UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002008
Receipt number R000002262
Scientific Title A non-randomized confirmatory study of Limited Surgical Resection for Peripheral Early Lung Cancer Defined with Thoracic Thin-section Computed Tomography (JCOG0804/WJOG4507L)
Date of disclosure of the study information 2009/05/26
Last modified on 2022/08/26 18:47:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A non-randomized confirmatory study of Limited Surgical Resection for Peripheral Early Lung Cancer Defined with Thoracic Thin-section Computed Tomography (JCOG0804/WJOG4507L)

Acronym

A non-randomized confirmatory study of Limited Surgical Resection for Peripheral Early Lung Cancer Defined with Thoracic Thin-section Computed Tomography (JCOG0804/WJOG4507L)

Scientific Title

A non-randomized confirmatory study of Limited Surgical Resection for Peripheral Early Lung Cancer Defined with Thoracic Thin-section Computed Tomography (JCOG0804/WJOG4507L)

Scientific Title:Acronym

A non-randomized confirmatory study of Limited Surgical Resection for Peripheral Early Lung Cancer Defined with Thoracic Thin-section Computed Tomography (JCOG0804/WJOG4507L)

Region

Japan


Condition

Condition

small (2 cm or less) peripheral radiological non-invasive lung cancer

Classification by specialty

Chest surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safery of limited resection (wedge resection in general) in patients with small (2 cm or less) peripheral radiological non-invasive lung cancer diagnosed by preoperative thin-section CT images.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

Relapse-free survival

Key secondary outcomes

overall survival, proportion of local recurrence, postoperative respiratory function, proportion of completion of limited resection, adverse events.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Limited pulmonary resection

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

79 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Contrast-enhanced thoracic CT fulfills all of the following conditions:
i) lung cancer is suspected,
ii) the number of tumor is three or less,
iii) center of tumor is located in the outer third of the lung field,
iv) no lymph node metastasis.
2) Thin-section CT fulfills both of the following conditions:
i) all tumors are diagnosed as radiological non-invasive cancer,
ii) maximum diameter of any tumor is 2 cm or less.
3) In case pathological or cytological examination is performed preoperatively, pathological diagnosis of the tumor fulfills both of the following conditions:
i) lung adenocarcinoma is suspected (including atypical adenomatous hyperplasia).
ii) all tumors are not diagnosed as being tumor other than adenocarcinoma.
4) Aged 20 to 79 years old.
5) No prior ipsilateral thoracotomy (prior diagnostic thoracoscopy is allowed).
6) No prior chemotherapy or radiation therapy for any malignant diseases (prior hormonal therapy is allowed).
7) Expected postoperative FEV1.0>=800 mL and PaO2>=65 torr.
8) Performance status of 0 or 1.
9) Sufficient organ functions.
10)Written informed consent.

Key exclusion criteria

1) simultaneous or metachronous (within the past 5 years) double cancers.
2) interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema.
3) active bacterial or fungous infection.
4) women during pregnancy or breast-feeding.
5) psychiatric disease.
6) systemic steroids medication.
7) diabetes mellitus treated with insulin or poorly controlled.
8) poorly controlled hypertension.
9) history of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months.

Target sample size

330


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masahiro Tuboi

Organization

National Cancer Center Hospital East

Division name

Division of Thoracic Surgery

Zip code


Address

6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, JAPAN

TEL

04-7133-1111

Email

mtsuboi@east.ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kenji Suzuki

Organization

JCOG0804 Study Coordinating Office

Division name

Division of Thoracic Surgery, Juntendo University

Zip code


Address

2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, JAPAN

TEL

03-3813-3111

Homepage URL

http://www.jcog.jp/

Email

JCOG_sir@ml.jcog.jp


Sponsor or person

Institute

Japan Clinical Oncology Group(JCOG)

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

West Japan Oncology Group (WJOG)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

旭川医科大学病院(北海道)
国立病院機構仙台医療センター(宮城県)
東北大学病院(宮城県)
山形県立中央病院(山形県)
山形県立中央病院(山形県)
日本海総合病院(山形県)
茨城県立中央病院・茨城県地域がんセンター(茨城県)
栃木県立がんセンター(栃木県)
群馬県立がんセンター(群馬県)
国立がん研究センター東病院(千葉県)
千葉県がんセンター(千葉県)
千葉大学医学部(千葉県)
千葉県がんセンター(千葉県)
国立がん研究センター中央病院(東京都)
杏林大学医学部(東京都)
東京医科大学病院(東京都)
がん・感染症センター都立駒込病院(東京都)
慶應義塾大学病院(東京都)
がん研究会有明病院(東京都)
順天堂大学医学部附属順天堂医院(東京都)
聖マリアンナ医科大学(神奈川県)
神奈川県立病院機構神奈川県立がんセンター(神奈川県)
横浜市立市民病院(神奈川県)
横浜市立大学附属市民総合医療センター(神奈川県)
神奈川県立循環器呼吸器病センター(神奈川県)
新潟県立がんセンター新潟病院(新潟県)
国立病院機構西新潟中央病院(新潟県)
金沢大学医学部(石川県)
石川県立中央病院(石川県)
岐阜市民病院(岐阜県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院(愛知県)
名古屋大学医学部(愛知県)
愛知県がんセンター愛知病院(愛知県)
名古屋大学医学部附属病院(愛知県)
三重大学医学部附属病院(三重県)
滋賀医科大学医学部附属病院(滋賀県)
京都大学医学部附属病院(京都府)
大阪大学医学部(大阪府)
大阪府立病院機構大阪府立成人病センター(大阪府)
大阪府立病院機構大阪府立呼吸器・アレルギー医療センター(大阪府)
国立病院機構近畿中央胸部疾患センター(大阪府)
大阪市立総合医療センター(大阪府)
大阪大学医学部附属病院(大阪府)
大阪市立大学医学部附属病院(大阪府)
国立病院機構大阪医療センター(大阪府)
国立病院機構刀根山病院(大阪府)
市立吹田市民病院(大阪府)
兵庫県立がんセンター(兵庫県)
神戸市立医療センター中央市民病院(兵庫県)
兵庫県立淡路医療センター(兵庫県)
近畿大学医学部奈良病院(奈良県)
倉敷中央病院(岡山県)
岡山大学病院(岡山県)
倉敷中央病院(岡山県)
川崎医科大学附属病院(岡山県)
国立病院機構呉医療センター・中国がんセンター(広島県)
広島大学病院(広島県)
広島市立広島市民病院(広島県)
広島市立安佐市民病院(広島県)
国立病院機構山口宇部医療センター(山口県)
国立病院機構四国がんセンター(愛媛県)
国立病院機構九州がんセンター(福岡県)
九州大学病院(福岡県)
長崎大学病院(長崎県)
日本赤十字社長崎原爆病院(長崎県)
熊本大学医学部(熊本県)
熊本中央病院(熊本県)
熊本大学医学部附属病院(熊本県)
大分大学医学部附属病院(大分県)
大分県立病院(大分県)
新別府病院(大分県)


Other administrative information

Date of disclosure of the study information

2009 Year 05 Month 26 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

https://pubmed.ncbi.nlm.nih.gov/33487427/

Number of participants that the trial has enrolled

333

Results

See the datails via "URL releasing results" above.
Also the details can be seen in the JCOG website:
http://www.jcog.jp/en/trials/index.html

Results date posted

2022 Year 08 Month 26 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2009 Year 03 Month 10 Day

Date of IRB

2009 Year 05 Month 08 Day

Anticipated trial start date

2009 Year 05 Month 26 Day

Last follow-up date

2025 Year 05 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is conducted as an intergroup study of Japan Clinical Oncology Group(JCOG) and West Japan Oncology Group(WJOG) .


Management information

Registered date

2009 Year 05 Month 26 Day

Last modified on

2022 Year 08 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002262


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name